Biogen beats third-quarter results on strength in rare disease drugs

What happened

Biogen beat Wall Street estimates for third-quarter results. Strong demand for rare disease and Alzheimer's drugs helped offset declining sales of multiple sclerosis treatments. Sales of eye disease drug Syfovre rose 27% to $191 million, and rare disease portfolio sales reached $676 million.

Confirmed

Global impact / market context

Biogen is shifting its revenue base away from older multiple sclerosis drugs, which face pricing pressure. Faster-growing rare disease and Alzheimer's treatments can replace shrinking sales, supporting future revenue. The $5.6 billion Apellis buyout adds Syfovre and Empaveli, which must justify that capital spending.

Analyst inference

Investors compare drugmakers on whether new products can offset declining older franchises. Biogen's beat shows rare disease and Alzheimer's demand beating expectations, while its multiple sclerosis portfolio shrinks. Upcoming trial results for litifilimab and felzartamab are the next catalysts that could change growth expectations.

Analyst inference

What to watch

1. Leqembi global sales rose 67% to about $202 million, beating analysts' average expectation of $130.6 million. Biogen is counting on U.S. approvals for an under-the-skin formulation to drive patient uptake. Confirmed
2. The company plans to lean on Syfovre, Empaveli, and rare disease drugs for growth. Watch whether these products sustain their current sales pace as pricing pressure continues on multiple sclerosis treatments. Proposed
3. Late-stage trial results over the next year for lupus drug litifilimab and kidney-disease treatment felzartamab could shape long-term growth. Failure or delay would weaken the replacement story for declining multiple sclerosis revenue. Analyst inference

Evidence

• Original source link unavailable